Navigation Links
Aridis Pharmaceuticals Expands Patent Portfolio for Several Fully Human Monoclonal Antibodies Against Infectious Disease Targets
Date:2/24/2016

SAN JOSE, Calif., Feb. 24, 2016 /PRNewswire/ -- Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, announced today that in addition to the previously announced European Patent Office (EPO) patent issuance, the U.S. Patent and Trademark Office has issued Aridis' patent covering composition-of-matter, method of production and method of treatment for AR-301 (Salvecin™).

AR-301, a fully human monoclonal antibody (mAb) that neutralizes Staphylococcus aureus alpha-toxin, is currently being evaluated in a Phase 2a clinical trial across the U.S. and several countries in Europe.  AR-301 is being tested as an adjunctive therapy to standard of care antibiotics to treat hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) and severe community-acquired pneumonia (CAP).  AR-301 was identified and developed through Aridis' propriety MabIgX™ technology by generating a hybridoma clone from B-cells of a recovered S. aureus bacteremia patient.  The antibody works by neutralizing S. aureus alpha-toxin, which is a critical factor involved in the establishment and persistence of S. aureus infection.

Additionally, the patents covering Aridis' human mAbs against the emerging Gram-negative bacterium Acinetobacter baumannii (A. baumannii), "AR-401," have also received notices of allowance in Europe and the U.S.

Vu Truong, Ph.D., Founder and Chief Executive Officer of Aridis, stated, "We are delighted to have successfully secured expanded patent protection for AR-301 and AR-401.  We are confident that the use of monoclonal antibodies to treat antibiotic resistant pathogens can have a broad impact on reducing healthcare costs by providing additional protection against infections.  The issuance of these patents adds to our already robust intellectual property estate covering our novel therapeutic antibodies, as well as our antibody discovery platform MabIgX®. Furthermore, significant progress has also been made toward the near-term allowance of patent application for Aridis' novel fully human monoclonal antibody against respiratory syncytial virus (RSV), AR-201."

About Aridis Pharmaceuticals, Inc.
Aridis is a privately held biopharmaceutical company applying proprietary monoclonal antibody discovery technology MabIgX™ to produce novel infectious disease focused therapies.  Aridis' product pipeline includes AR-101 (Aerumab™) anti-Pseudomonas aeruginosa LPS human monoclonal antibody; AR-301 (Salvecin™) anti-Staphylococcus aureus human monoclonal antibody to treat acute pneumonia; Aerucin™, a broadly reactive anti-Pseudomonas aeruginosa human monoclonal antibody initially being developed to treat acute pneumonia; Panaecin™, a small molecule anti-infective gallium compound with broad spectrum activities against bacteria, viruses, and fungi; AR- 401 anti-Acinetobacter baumannii human monoclonal antibody; and AR-201 anti-RSV human monoclonal antibody.

Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties.  Such forward-looking statements include statements relating to the therapeutic applications of Aerumab™ (AR-101), Salvecin™ (AR-301), Aerucin™, Panaecin™, AR-401, AR-201, Aridis' proprietary formulation and delivery technologies, about Aridis' strategy, pre-clinical and clinical programs, and ability to identify and develop drugs, as well as other statements that are not historical facts. Actual events or results may differ materially from Aridis' expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the timing, success and cost of Aridis' research and clinical studies and its ability to obtain additional financing.  These forward-looking statements represent Aridis' judgment as of the date of this release. Aridis disclaims any intent or obligation to update these forward-looking statements.

Contacts:

Tiberend Strategic Advisors, Inc. 
Joshua Drumm, Ph.D. (investors) 
jdrumm@tiberend.com 
(212) 375-2664

Andrew Mielach (media)
amielach@tiberend.com 
(212) 375-2694

 


'/>"/>
SOURCE Aridis Pharmaceuticals, Inc.
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board
2. Aridis Pharmaceuticals Adds Craig Gibbs, Ph.D., MBA, to Board of Directors
3. Aridis Pharmaceuticals Expands Phase 2a Trial Into the U.S. for Monoclonal Antibody AR-301 for the Treatment of Acute Pneumonia
4. Aridis Pharmaceuticals Appoints Fred Kurland as Chief Financial Officer
5. Aridis Pharmaceuticals Receives FDA Fast Track Designation for AR-301 for Acute Pneumonia caused by Staphylococcus aureus
6. Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
7. Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeants Board of Directors
8. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
9. Access Pharmaceuticals Reports First Quarter Results
10. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
11. Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... , May 10, 2017 Radiology has become ... its costs have also spiraled to the number one ... to radiology than ever before as the most complete ... a patient with lower back pain an MRI may ... reason for pain, resulting in entirely different treatment protocols.  ...
(Date:5/9/2017)...  Semler Scientific, Inc. (OTCQB: SMLR), an emerging ... the clinical effectiveness and efficiency of healthcare providers, ... ended March 31, 2017. "We ... identify when preventive care options are appropriate, which ... attacks or strokes occur," said Doug Murphy-Chutorian ...
(Date:5/6/2017)...  Hill-Rom Holdings, Inc. (NYSE: HRC), has begun a ... to its Welch Allyn campus. The ... more than 100 new jobs to Central ... a significant presence for more than 100 years. Hill-Rom,s ... large portion of which will be R&D and engineering ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... May 26, 2017 , ... Leading ... 2017 on May 30th and 31st at The Four Seasons Hotel Boston. ... in the life sciences, offering exclusive access to key decision makers who influence ...
(Date:5/26/2017)... ... May 26, 2017 , ... Amir Qureshi, MD is the first physician ... spinal cord stimulation system. The Nuvectra™ Algovita SCS System has been FDA approved as ... the first in Arkansas to introduce the most powerful SCS system and the only ...
(Date:5/26/2017)... ... ... A new analysis of community health data reveals that four out of the ... the average cost of healthcare rising and the U.S. senior population expected to double ... of where they live. An annual 2017 report looked at a variety of community ...
(Date:5/26/2017)... ... 26, 2017 , ... via seating is proud to partner ... chair specifically designed for clinical areas. Genie Copper Mesh is a crossover chair ... to provide customers with a game changing chair that is affordably priced,” Chas ...
(Date:5/26/2017)... ... May 26, 2017 , ... After raising nearly $30,000 on Kickstarter ... to be available at a discounted crowdfunding price on Indiegogo . , “Along ... I also wanted to bring a fidget toy to the market that was made ...
Breaking Medicine News(10 mins):